Syncom Formulations (India) Limited Financial Ratios
SYNCOMF · Healthcare · Current price ₹22.01
P/E ratio
27.2x
P/B ratio
5.4x
ROE
0.0%
ROCE
24.6%
Debt / Equity
0.00
Dividend yield
0.5%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | 27.2x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 5.4x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | 0.0% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | 24.6% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 0.00 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with Syncom Formulations (India) Limited's latest numbers.
Syncom Formulations (India) Limited profitability
Syncom Formulations (India) Limited generates a return on equity of 0.0% and a return on capital employed of 24.6%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 0.00 and a P/E of 27.2x, Syncom Formulations (India) Limited is conservatively financed. Our overall business-quality score for the company is 6.2 / 10.
Understand the ratios
More on Syncom Formulations (India) Limited
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.